secwatch.observer — SEC 8-K summary
======================================

Issuer:     NKGen Biotech, Inc. (—)
CIK:        0001845459
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001213900-26-020876
Event type: debt
Sentiment:  neutral
Materiality: 0.45
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NKGen Biotech secures additional $343K loan from AlpineBrook; total note principal rises to $27.1M
--------------------------------------------------------------------------------

- Additional $343,000 loan from AlpineBrook Capital; total secured note principal increased to $27,101,106.
- Loan funded on Feb 20, 2026; interest accrues from that date.
- This is the fifth amendment to the note, with prior amendments in January 2026.
- Borrowers include NKGen Biotech and NKGen Operating Biotech; CEO Paul Song signed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845459/000121390026020876/0001213900-26-020876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845459/000121390026020876/ea0277453-8k_nkgenbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-020876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer